AR116526A1 - Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g - Google Patents

Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g

Info

Publication number
AR116526A1
AR116526A1 ARP190102737A ARP190102737A AR116526A1 AR 116526 A1 AR116526 A1 AR 116526A1 AR P190102737 A ARP190102737 A AR P190102737A AR P190102737 A ARP190102737 A AR P190102737A AR 116526 A1 AR116526 A1 AR 116526A1
Authority
AR
Argentina
Prior art keywords
hla
mediated
suppression
seq
inhibits
Prior art date
Application number
ARP190102737A
Other languages
English (en)
Original Assignee
Tizona Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tizona Therapeutics filed Critical Tizona Therapeutics
Publication of AR116526A1 publication Critical patent/AR116526A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

En el presente documento se proporcionan anticuerpos que se unen selectivamente a HLA-G y composiciones que comprenden los anticuerpos. También se proporcionan métodos para usar los anticuerpos, tales como métodos terapéuticos y de diagnóstico. Reivindicación 1: Un anticuerpo que se une específicamente a un HLA-G humano (hHLA-G) y es capaz de 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 ó 16 de los siguientes: a) inhibir una función inmunosupresora de HLA-G; b) bloquear la interacción y/o unión de HLA-G a ILT2; c) bloquear la interacción y/o unión de HLA-G a ILT4; d) bloquear la interacción y/o unión de HLA-G a KIR2DL4; e) inhibir la supresión de células NK mediada por HLA-G; f) inhibir la supresión de linfocitos T citotóxicos mediada por HLA-G; g) inhibir la supresión de células B mediada por HLA-G; h) inhibir la supresión de neutrófilos mediada por HLA-G; i) inhibir la supresión de monocitos mediada por HLA-G; j) inhibir la supresión de macrófagos mediada por HLA-G; k) inhibir la supresión de células dendríticas mediada por HLA-G; l) inhibir la supresión de la citólisis y/o proliferación de células NK y/o T mediada por HLA-G; m) inhibir la supresión por HLA-G de células mieloides; n) inhibir la supresión de fagocitosis mediada por HLA-G; o) inhibir la generación, expansión o función mediada por HLA-G de células reguladoras T; o p) inhibir metástasis. Reivindicación 3: Una composición farmacéutica que comprende una cantidad efectiva de un anticuerpo que se une a hHLA-G y tiene 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, ó 16 de las siguientes características: a) inhibe una función inmunosupresora de HLA-G; b) bloquea la interacción y/o unión de HLA-G a ILT2; c) bloquea la interacción y/o unión de HLA-G a ILT4; d) bloquea la interacción y/o unión de HLA-G a KIR2DL4; e) inhibe la supresión de células NK mediada por HLA-G; f) inhibe la supresión de linfocitos T citotóxicos mediada por HLA-G; g) inhibe la supresión de células B mediada por HLA-G; h) inhibe la supresión de neutrófilos mediada por HLA-G; i) inhibe la supresión de monocitos mediada por HLA-G; j) inhibe la supresión de macrófagos mediada por HLA-G; k) inhibe la supresión de células dendríticas mediada par HLA-G; l) inhibe la supresión de la citólisis y/o proliferación de células NK y/o T mediada por HLA-G; m) inhibe la supresión por HLA-G de células mieloides; n) inhibe la supresión de fagocitosis mediada por HLA-G; o) inhibe la generación o expansión mediada HLA-G de células reguladoras T; o p) inhibe metástasis. Reivindicación 10: El anticuerpo de conformidad con la reivindicación 1, que comprende una región constante de la cadena pesada humana o fragmento o una variante de la misma y/o una región constante de la cadena ligera o fragmento o variante de la misma, en donde la región constante o fragmento de la variante del mismo comprende hasta 20 sustituciones de aminoácidos conservadoramente modificadas de cualquier secuencia expuesta en SEQ ID Nº 170 - 200 y/o SEQ ID Nº 204 - 228. Reivindicación 11: Una molécula de anticuerpo aislada capaz de unirse a HLA-G humano (hHLA-G), que comprende una región variable de la cadena pesada (VH) y una región variable de la cadena ligera (VL), en donde la VH y/o VL comprende 1, 2, 3, 4, 5 ó 6 de: a) una VHCDR1 que tiene la secuencia establecida en SEQ ID Nº 1 - 14 o SEQ ID Nº 18 - 34, b) una VHCDR2 que tiene la secuencia establecida en SEQ ID Nº 38 - 50 o SEQ ID Nº 54 - 71, c) una VHCDR3 que tiene la secuencia establecida en SEQ ID Nº 76 - 101, d) una VLCDR1 que tiene la secuencia establecida en SEQ ID Nº 105 - 124, e) una VLCDR2 que tiene la secuencia establecida en SEQ ID Nº 128 - 145, y f) una VLCDR3 que tiene la secuencia establecida en SEQ ID Nº 149 - 166. Reivindicación 13: Una molécula de anticuerpo aislada capaz de unirse a HLA-G humano (hHLA-G), que comprende una región variable de la cadena pesada (VH) y/o una región variable de la cadena ligera (VL), en donde la VH comprende al menos una secuencia establecida en cualquiera de SEQ ID Nº 170 - 200 y la VL comprende al menos una secuencia establecida en cualquiera de SEQ ID Nº 204 - 228. Reivindicación 14: Un ácido nucleico aislado que codifica para el anticuerpo de conformidad con la reivindicación 1, la reivindicación 12 o la reivindicación 13. Reivindicación 15: Un vector de expresión que comprende el ácido nucleico de conformidad con la reivindicación 14. Reivindicación 16: Una célula hospedera procariota o eucariota que comprende el vector de conformidad con la reivindicación 15. Reivindicación 17: Un virus oncolítico que codifica para el ácido nucleico de conformidad con cualquiera de las reivindicaciones 14 - 16. Reivindicación 18: Un método para la producción de una proteína recombinante que comprende las etapas de expresar el ácido nucleico de conformidad con la reivindicación 14 o la reivindicación 15 en una célula hospedera procariota o eucariota y recuperar la proteína de la célula o del sobrenadante del cultivo celular. Reivindicación 19: Un método para el tratamiento de un sujeto que padezca cáncer, una infección crónica o una enfermedad inflamatoria, que comprende la etapa de administrar al sujeto una composición farmacéutica que comprenda una cantidad eficaz del anticuerpo de conformidad con la reivindicación 1 o la composición farmacéutica de conformidad con la reivindicación 3. Reivindicación 21: El método de conformidad con la reivindicación 19, en donde el cáncer es un cáncer hematológico.
ARP190102737A 2018-09-27 2019-09-26 Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g AR116526A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862737666P 2018-09-27 2018-09-27

Publications (1)

Publication Number Publication Date
AR116526A1 true AR116526A1 (es) 2021-05-19

Family

ID=68296637

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102737A AR116526A1 (es) 2018-09-27 2019-09-26 Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g

Country Status (24)

Country Link
US (3) US20210340259A1 (es)
EP (1) EP3856780A1 (es)
JP (1) JP2022502052A (es)
KR (1) KR20210098956A (es)
CN (2) CN115057932A (es)
AR (1) AR116526A1 (es)
AU (1) AU2019346598A1 (es)
BR (1) BR112021005868A2 (es)
CA (1) CA3114407A1 (es)
CL (2) CL2021000761A1 (es)
CO (1) CO2021004719A2 (es)
CR (1) CR20210197A (es)
DO (1) DOP2021000049A (es)
EA (1) EA202190609A1 (es)
EC (1) ECSP21026339A (es)
IL (1) IL281778A (es)
MX (1) MX2021003555A (es)
PE (1) PE20211767A1 (es)
PH (1) PH12021550690A1 (es)
SG (1) SG11202103104RA (es)
TW (1) TWI828767B (es)
UY (1) UY38391A (es)
WO (1) WO2020069133A1 (es)
ZA (1) ZA202102034B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019302454A1 (en) 2018-07-09 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to ILT4
CN115996952A (zh) * 2020-06-11 2023-04-21 提圣纳医疗公司 对hla-g和另一种抗原具有结合特异性的双特异性免疫细胞接合子
JP2024504384A (ja) * 2021-01-21 2024-01-31 ツイスト バイオサイエンス コーポレーション アデノシン受容体に関する方法および組成物
US20220306747A1 (en) * 2021-03-24 2022-09-29 China Medical University Hospital Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same
US11795227B2 (en) * 2021-03-24 2023-10-24 Shine-On Biomedical Co., Ltd. Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
CN115925930A (zh) * 2021-11-04 2023-04-07 台州恩泽医疗中心(集团) 一种抗hla-g1、hla-g4及hla-g5异构体分子的单克隆抗体及其用途
WO2023182866A1 (ko) * 2022-03-25 2023-09-28 에이치케이이노엔 주식회사 Hla-g 특이적 항체 및 이의 용도
CN115819583A (zh) * 2022-03-31 2023-03-21 台州恩泽医疗中心(集团) 一种抗hla-g分子的单克隆抗体及其用途
TW202346367A (zh) * 2022-04-08 2023-12-01 美商提聖納醫療公司 涉及抗ｈｌａ－ｇ抗體及抗ｅｇｆｒ抗體、抗ｐｄ１或抗ｐｄ－ｌ１抗體、及／或抗ｃｄ４７抗體之組合療法
CN117448412A (zh) * 2022-07-26 2024-01-26 中山大学孙逸仙纪念医院 CD158d分子、其中和抗体，及应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993016177A1 (en) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
CA2213620A1 (en) 1995-04-07 1996-10-10 The Regents Of The University Of California Antibodies for the detection of hla-g
CA2321222A1 (fr) 1998-02-20 1999-08-26 Commissariat A L'energie Atomique Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications
CA2425186A1 (en) 2000-09-15 2002-03-21 University Of Kansas Medical Center Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g
ES2430857T3 (es) 2000-12-18 2013-11-22 Dyax Corp. Bibliotecas focalizadas de paquetes genéticos
FR2856599A1 (fr) 2003-06-30 2004-12-31 Commissariat Energie Atomique Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang.
WO2005042693A2 (ja) 2003-11-04 2005-05-12 The Animal Engineering Research Institute Ｈｌａ−ｅキメラ分子
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CN1312182C (zh) 2004-10-26 2007-04-25 四川新创生物科技有限公司 抗hla－g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
BRPI0816785A2 (pt) 2007-09-14 2017-05-02 Adimab Inc bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas
WO2010150233A2 (en) 2009-06-25 2010-12-29 Commissariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
CN101967191A (zh) 2009-07-28 2011-02-09 广州天美生物技术有限公司 Hla-g抗体制备方法及其在医学中的应用
MX360336B (es) 2010-07-16 2018-10-30 Adimab Llc Star Colecciones de anticuerpos.
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
US10156574B2 (en) 2013-04-29 2018-12-18 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
WO2016160622A2 (en) 2015-03-27 2016-10-06 University Of Southern California Hla-g as a novel target for car t-cell immunotherapy
CN114990141A (zh) 2015-05-15 2022-09-02 希望之城 嵌合抗原受体组合物
EA201892793A1 (ru) * 2016-06-03 2019-06-28 Инвектис Анти-hla-g специфические антитела
TW201829463A (zh) * 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AU2019328677A1 (en) 2018-08-31 2021-04-01 Invectys SA Chimeric antigen receptors against multiple HLA-G isoforms

Also Published As

Publication number Publication date
PE20211767A1 (es) 2021-09-07
IL281778A (en) 2021-05-31
CA3114407A1 (en) 2020-04-02
CL2021000761A1 (es) 2021-09-10
EP3856780A1 (en) 2021-08-04
DOP2021000049A (es) 2021-10-31
EA202190609A1 (ru) 2021-08-17
CN115057932A (zh) 2022-09-16
BR112021005868A2 (pt) 2021-10-19
TWI828767B (zh) 2024-01-11
AU2019346598A1 (en) 2021-04-29
US20210340259A1 (en) 2021-11-04
US20200102390A1 (en) 2020-04-02
TW202035456A (zh) 2020-10-01
ZA202102034B (en) 2022-09-28
PH12021550690A1 (en) 2022-02-28
JP2022502052A (ja) 2022-01-11
UY38391A (es) 2020-04-30
CN113166243A (zh) 2021-07-23
KR20210098956A (ko) 2021-08-11
CR20210197A (es) 2021-06-03
US11208487B2 (en) 2021-12-28
CO2021004719A2 (es) 2021-05-31
MX2021003555A (es) 2021-05-27
CN113166243B (zh) 2023-03-24
ECSP21026339A (es) 2021-07-30
WO2020069133A1 (en) 2020-04-02
CL2023002048A1 (es) 2023-12-22
SG11202103104RA (en) 2021-04-29
US20220135689A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
AR116526A1 (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g
EP4249068A2 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
JP2018524326A5 (es)
PE20190911A1 (es) Composiciones y anticuerpos anti-lag-3
AR110101A1 (es) Miembros de unión (2)
JP2019525771A5 (es)
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
EA201992755A1 (ru) Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4)
PE20171324A1 (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
JP2016536322A5 (es)
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
JP2020512820A (ja) 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域
RU2016114504A (ru) Би- или полиспецифические полипептиды, связывающие поверхностные антигены иммунных эффекторных клеток и антигены hbv для лечения инфекций bv и ассоциированных с ними состояний
AR075504A1 (es) Moleculas de anticuerpos que tienen especificidad para el ox40 humano
AR109533A2 (es) Anticuerpos anti-fractalkina o un fragmento de unión a la fkn de éste, composiciones que lo comprenden y métodos para tratar trastornos inflamatorios
AR109264A1 (es) Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
CA3108951A1 (en) Single-chain chimeric polypeptides and uses thereof
JP2016512216A5 (es)
US11945863B2 (en) CD33-, CD16- and CD123-specific single chain triplebody
AR122761A1 (es) Moléculas de unión a antígeno biespecíficas anti-cd3 / anti-cd28
WO2015036582A2 (en) Tetravalent homodimeric antigen-binding proteins
AR109450A1 (es) Moléculas de unión a ilt7 y métodos de uso de las mismas
AR109683A1 (es) Anticuerpos contra el factor xi y sus usos
BR112019013955A2 (pt) Composições e métodos relacionados a construtos de fc manipulados
JP2018527323A5 (es)